Journal of Ophthalmology

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability


Publishing date
01 Feb 2012
Status
Published
Submission deadline
01 Aug 2011

Lead Editor

1Department of Ophthalmology, Faculty of Medicine, Oita University, Japan

2Department of Ophthalmology and Visual Science, Graduate School of Biomedical Sciences, Hiroshima University, Japan

3Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L69 3BX, UK


Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability

Description

Recent clinical trials of the intravitreal injection of anti-VEGF agents (ranibizumab, bevacizumab) have shown excellent results in the treatment of angiogenic pathologies including choroidal neovascularization, proliferative diabetic retinopathy, and neovascular glaucoma. Bleeding from the retinal vessels or new vessels during a standard vitrectomy after intravitreal injection of bevacizumab (IVB) has been reported to occur significantly less frequently than that observed during a standard vitrectomy without bevacizumab therapy. IVB has also been reported to be effective in the regression of new vessels in PDR and neovascular glaucoma (NVG). This injection may provide us with sufficient time to treat these patients with retinal photocoagulation. In addition, it may also be used as an adjunctive therapy for a mitomycin C (MMC) trabeculectomy to treat NVG.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the mechanisms of the clinical effects of anti-VEGF drug therapy, as well as the evaluation of their outcomes. Ranibizumab is used worldwide for the treatment of age-related macular degeneration. We are particularly interested in articles describing the effect of other anti-VEGF drugs trials; mechanisms of the effect of anti-VEGF agents; evaluation of outcomes for macular edema, PDR, neovascular glaucoma, and other diseases. Potential topics include, but are not limited to:

  • Mechanisms of the effect of anti-VEGF agents for angiogenic pathologies
  • Pathological changes after the anti-VEGF therapies
  • Evaluations of outcomes of anti-VEGF therapy for various ocular diseases
  • OCT and angiographic images after anti-VEGF therapy
  • New approach of anti-VEGF agents

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jop/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2012
  • - Article ID 898207
  • - Editorial

Anti-Vascular Endothelial Growth Factor Agents for Ocular Angiogenesis and Vascular Permeability

Toshiaki Kubota | Yoshiaki Kiuchi | Carl Sheridan
  • Special Issue
  • - Volume 2012
  • - Article ID 637316
  • - Review Article

New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration

Young Gun Park | Hyun Wook Rhu | ... | Young Jung Roh
  • Special Issue
  • - Volume 2012
  • - Article ID 209538
  • - Review Article

Vascular Complications and Diabetes: Current Therapies and Future Challenges

Abbott L. Willard | Ira M. Herman
  • Special Issue
  • - Volume 2012
  • - Article ID 483034
  • - Review Article

Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians

Pearse A. Keane | Srinivas R. Sadda
  • Special Issue
  • - Volume 2012
  • - Article ID 154659
  • - Clinical Study

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration

Tomoko Nakamura | Akio Miyakoshi | ... | Atsushi Hayashi
  • Special Issue
  • - Volume 2012
  • - Article ID 861384
  • - Clinical Study

Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity

Leila El Matri | Rym Bouraoui | ... | Hana Landoulsi
  • Special Issue
  • - Volume 2012
  • - Article ID 319728
  • - Review Article

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration

Ilias Zampros | Anna Praidou | ... | Sofia Androudi
  • Special Issue
  • - Volume 2012
  • - Article ID 852183
  • - Review Article

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability

Kenichi Kimoto | Toshiaki Kubota
Journal of Ophthalmology
 Journal metrics
Acceptance rate36%
Submission to final decision73 days
Acceptance to publication31 days
CiteScore2.800
Impact Factor1.447
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.